The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. We have dedicated our funding to several key areas through 4 funding mechanisms: Drug Development, Program to Accelerate Clinical Trials (PACT), Neuroimaging and CSF Biomarker Development, and Prevention Pipeline.

FUNDING MECHANISMS

Drug Development RFP: The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer's disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application.

Program to Accelerate Clinical Trials (PACT) RFP: The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer's disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered.

Neuroimaging and CSF Biomarker Development RFP: The aim of this RFP is to further develop and validate established biomarkers for which there is a clear clinical need in Alzheimer's disease and related dementias. This RFP prioritizes biomarkers with a defined context of use, a clear advantage over other relevant biomarkers, and a path to commercialization and/or clinical use.

Prevention Pipeline RFP: The ADDF seeks to support studies of cognitive symptoms due to health conditions, comparative effectiveness research, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Duration

Drug development: 1 year, potential for follow-up funding

Program to accelerate clinical trials : multi-year, potential for follow-up funding

Neuroimaging and CSF biomarker development program: 1 year, potential for follow-up funding. multi-year proposals can be considered

Prevention pipeline: multi-year, potential for follow-up funding

Funding

Drug development: up to $600,000

Program to accelerate clinical trials : up to $3 million

Neuroimaging and CSF biomarker development program: up to $600,000

Prevention pipeline: up to $3 million for clinical trials

Deadlines for 2021 RFPs:
 

LETTERS OF INTENT:

February 5,

May 28

October 1

INVITED FULL PROPOSALS:

April 16

July 30

December 3